Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Frederick J. Kohlhapp Clear advanced filters

  • As presented at the 2026 ASCO Annual Meeting, in a phase 1 trial, treatment of patients with the seizure-related homolog protein 6 (SEZ6)-targeting antibody−drug conjugate ABBV-706 demonstrated a manageable safety profile and showed preliminary clinical efficacy in patients with resistant or refractory small cell lung cancer.

    • Lauren Averett Byers
    • Byoung Chul Cho
    • Sreenivasa Chandana
    ResearchOpen Access
    Nature Medicine
    P: 1-11

  • CD8+ T cells primed in the absence of CD4+ T cell help fail to develop a robust memory cell response. Zloza et al. now report that these CD4-unhelped CD8+ T cells can be rescued by activating their cell surface receptor NKG2D, which restores CD8+ T cell expansion and cytolytic activity during a recall response and protection in a mouse model of influenza infection.

    • Andrew Zloza
    • Frederick J Kohlhapp
    • José A Guevara-Patiño
    Research
    Nature Medicine
    Volume: 18, P: 422-428

  • The death receptor CD95/Fas induces apoptosis of many normal cells but prevents necrotic death of cancer cells. Here the authors demonstrate that CD95 activation promotes a cancer stem cell (CSC) phenotype, and that CSCs but not differentiated cancer cells are resistant to CD95-mediated apoptosis and depend on CD95 signalling to prevent necrosis.

    • Paolo Ceppi
    • Abbas Hadji
    • Marcus E. Peter
    Research
    Nature Communications
    Volume: 5, P: 1-13

  • Oncolytic viruses can kill tumour cells through a dual mechanism of action; the direct lysis of cells, and the induction of an immune response. The first oncolytic virus has been approved in China, and another has been recommended for approval in the United States. This Review discusses the biology of oncolytic viruses as well as key oncolytic viruses in clinical development, and investigates the challenges associated with developing oncolytic viruses as a new therapeutic modality for cancer.

    • Howard L. Kaufman
    • Frederick J. Kohlhapp
    • Andrew Zloza
    Reviews
    Nature Reviews Drug Discovery
    Volume: 14, P: 642-662